Therefore, blocking upstream RAS signaling is a potential treatment strategy for CRC with Class 3 BRAF mutations, and also provides a theoretical basis for the stratified treatment of BRAF mutations [22,23]. The gene discussed is BRAF; the disease is colorectal carcinoma.